Actively Recruiting
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Led by Shanghai Gynecologic Oncology Group · Updated on 2025-02-10
220
Participants Needed
9
Research Sites
254 weeks
Total Duration
On this page
Sponsors
S
Shanghai Gynecologic Oncology Group
Lead Sponsor
F
Fudan University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Optimal Timing of Surgery combined with Maintenance Therapy in the Front-line Treatment of Advanced Ovarian Cancer
CONDITIONS
Official Title
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female aged 18 years or older
- Pathologically confirmed stage IIIC or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma
- Low, middle, or high tumor burden with a cPCI score of 12 or less based on pre-operative CT or PET/CT
- Complete cytoreduction is achievable based on imaging
- Willingness to undergo BRCA and HRD testing
- Performance status (ECOG) of 0 to 2
- Adequate bone marrow, kidney, and liver function to receive chemotherapy and surgery:
- White blood cells >3,000/µL, absolute neutrophil count ≥1,500/µL, platelets ≥100,000/µL, hemoglobin ≥9 g/dL
- Serum creatinine <1.25 times the upper normal limit (UNL) or creatinine clearance ≥60 mL/min
- Serum bilirubin <1.25 times UNL, AST and ALT <2.5 times UNL
- Ability to comply with the study protocol and follow-up
- Provided written informed consent
You will not qualify if you...
- Non-epithelial ovarian malignancies and borderline tumors
- Low grade ovarian cancer
- Mucinous ovarian cancer
- Inability to achieve complete cytoreduction due to metastases or unresectable disease
- Known hypersensitivity to olaparib, bevacizumab, or their components
- Other cancers within 5 years except carcinoma in situ, thyroid carcinoma, or early-stage breast carcinoma without relapse
- Medical conditions contraindicating surgery or chemotherapy that impair protocol adherence
- Factors such as religious or psychological issues affecting informed consent or study compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
The First People's Hospital of Foshan
Foshan, China
Actively Recruiting
2
Sun Yet-Sen University Cancer Center
Guangzhou, China
Actively Recruiting
3
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
Actively Recruiting
4
Zhejiang Cancer Hospital
Hangzhou, China
Actively Recruiting
5
The First Affiliated Hospital of University of Science and Technology of China
Hefei, China
Actively Recruiting
6
Fudan University Cancer Hospital
Shanghai, China
Actively Recruiting
7
Obstetrics and Gynecology Hospital of Fundan University
Shanghai, China
Actively Recruiting
8
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Actively Recruiting
9
Zhongshan Hospital, Fudan University
Shanghai, China
Actively Recruiting
Research Team
L
Libing Xiang
CONTACT
R
Rong Jiang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here